CIPLA's weekly return of 3.64% outperformed SUNPHARMA and GRASIM, but underperformed DIVISLAB. The stock's volatility of 24.74% was higher than its peers, indicating a riskier investment. Despite this, CIPLA's Sharpe Ratio of 0.58 suggests that its return was relatively attractive considering the risk taken. The Max Drawdown of -0.85% indicates a moderate level of risk.

[Volatility: 24.74%]